46049-49-4

Basic information

• Product Name: (S)-2,3-dihydro-1,4-Benzodioxin-2-methanamine
• Synonyms: (S)-2,3-dihydro-1,4-Benzodioxin-2-methanamine;(S)-(2,3-dihydrobenzo[b][1,4]dioxin-2-yl)methanamine;1-[(2S)-2,3-dihydro-1,4-benzodioxin-2-yl]MethanaMine
• CAS NO: 46049-49-4
• Molecular Formula: C₉H₁₁NO₂
• Molecular Weight: 165.19
• Mol File: 46049-49-4.mol
• Article Data: 20

Chemical Properties

• Boiling Point: 266.024 °C at 760 mmHg
• Flash Point: 124.098 °C
• Appearance: /
• Density: 1.154 g/cm³
• Vapor Pressure: 0.00885mmHg at 25°C
• Refractive Index: 1.545
• Storage Temp.: under inert gas (nitrogen or Argon) at 2–8 °C
• CAS DataBase Reference: (S)-2,3-dihydro-1,4-Benzodioxin-2-methanamine(CAS DataBase Reference)
• NIST Chemistry Reference: (S)-2,3-dihydro-1,4-Benzodioxin-2-methanamine(46049-49-4)
• EPA Substance Registry System: (S)-2,3-dihydro-1,4-Benzodioxin-2-methanamine(46049-49-4)

Safety Data

• Hazardous Substances Data: 46049-49-4(Hazardous Substances Data)

Usage

General Description

"(S)-2,3-dihydro-1,4-Benzodioxin-2-methanamine" is a specific compound with a complex chemical structure. Its systematic structure suggests that it belongs to the class of organic compounds known as benzodioxins, which are aromatic heterocyclic compounds with a system composed of two benzene rings joined by two oxygen atoms organized in a 1,4-arrangement and a 2,3-dihydroxy structure. This complex molecule also features a methanamine group, which is an amine consisting of one carbon atom attached to three hydrogen atoms, revealing its organic nature and potential for bioactivity. However, there is very less information readily available on this compound, particularly in regards to its physical properties, potential applications, or health and safety considerations.

InChI:InChI=1/C9H11NO2/c10-5-7-6-11-8-3-1-2-4-9(8)12-7/h1-4,7H,5-6,10H2/t7-/m0/s1

Upstream product

• 4442-59-5 (2,3-dihydrobenzo[1,4]dioxin-2-ylmethyl)amine 
• 1448449-66-8 C₉H₁₁NO₂*C₈H₈O₃ 
• 3663-80-7 1,4-benzodioxane-2-carboxylic acid 
• 98572-00-0 (S)-2-hydroxymethyl-1,4-benzodioxane 
• 120-80-9 benzene-1,2-diol 
• 113826-06-5 (R)-glycidyl tosylate 
• 1074-82-4 potassium phtalimide 
• 98-59-9 p-toluenesulfonyl chloride 
• 23191-07-3 (-)-Aminomethylbenzodioxan hydrochloride 
• 62501-68-2 (2S)-3-(2'-benzyloxyphenoxy)-1,2-propanediol ditosylate 
• 62501-69-3 (2S)-3-(2'-hydroxyphenoxy)-1,2-propanediol ditosylate 
• 62501-70-6 (R)-(2,3-dihydrobenzo[b][1,4] dioxin-2-yl)methyl 4-methylbenzenesulfonate 
• 650597-68-5 (R)-2-((mesyloxy)methyl)-1,4-benzodioxane 
• 62501-67-1 (2R)-3-(2'-benzyloxyphenoxy)-1,2-propanediol 

Downstream Products

• 77133-43-8 (S)-WB-4101 
• 1191886-06-2 C₂₅H₂₃NO₆ 
• 1191886-05-1 C₂₅H₂₃NO₅ 
• 1448661-63-9 (S)-2-[((2-(N-Cbz)-(6-methoxy-2,3-dihydro-7-indolyloxy)ethyl)amino)methyl]-1,4-benzodioxane 
• 98572-00-0 (S)-2-hydroxymethyl-1,4-benzodioxane 
• 650597-66-3 (R)-methyl 2,3-dihydrobenzo[b][1,4]dioxine-2-carboxylate 

Relevant articles and documents

SUBSTITUTED FUSED PYRIMIDINE COMPOUNDS AND USES THERE

Disclosed are new small molecules having a substituted pyrimidine or substituted fused pyrimidine core structure and the uses thereof for modulating glucocerebrosidase activity. Also disclosed are pharmaceutical compositions comprising the small molecules

Novel, broad-spectrum anticonvulsants containing a sulfamide group: Pharmacological properties of (S)- N -[(6-chloro-2,3-dihydrobenzo[1,4]dioxin-2- yl)methyl]sulfamide (JNJ-26489112)

Broad-spectrum anticonvulsants are of considerable interest as antiepileptic drugs, especially because of their potential for treating refractory patients. Such "neurostabilizers" have also been used to treat other neurological disorders, including migraine, bipolar disorder, and neuropathic pain. We synthesized a series of sulfamide derivatives (4-9, 10a-i, 11a, 11b, 12) and evaluated their anticonvulsant activity. Thus, we identified promising sulfamide 4 (JNJ-26489112) and explored its pharmacological properties. Compound 4 exhibited excellent anticonvulsant activity in rodents against audiogenic, electrically induced, and chemically induced seizures. Mechanistically, 4 inhibited voltage-gated Na+ channels and N-type Ca2+ channels and was effective as a K+ channel opener. The anticonvulsant profile of 4 suggests that it may be useful for treating multiple forms of epilepsy (generalized tonic-clonic, complex partial, absence seizures), including refractory (or pharmacoresistant) epilepsy, at dose levels that confer a good safety margin. On the basis of its pharmacology and other favorable characteristics, 4 was advanced into human clinical studies.

COMPOSITIONS AND METHODS FOR CYCLOFRUCTANS AS SEPARATION AGENTS

The present invention relates to derivatized cyclofructan compounds, compositions comprising derivatized cyclofructan compounds, and methods of using compositions comprising derivatized cyclofructan compounds for chromatographic separations of chemical species, including enantiomers. Said compositions may comprise a solid support and/or polymers comprising derivatized cyclofructan compounds.